Dueling Records: Are Statements in Your 510(k) Putting Your Patents at Risk?
28 October 2015
Attorneys Jolene Fernandes, James Ewing, Lisamarie Collins, Jacki Lin and Linda Wu contributed an article to Bloomberg BNA’s Medical Devices Law & Industry Report, “Dueling Records: Are Statements in Your 510(k) Putting Your Patents at Risk?,” on October 28, 2015. The article laboratory developed test (LDT) providers and new U.S. Food and Drug Administration (FDA) oversight that requires LDTs providers to consider if their LDTs constitute moderate-risk or high-risk devices subject to FDA oversight. The article reviews emerging areas of regulation for LDT providers; 510(k) statements and real world consequences to patent assets; and practical solutions for mitigating risk.
Author(s)
Related Insights
09 May 2024
Events
The FTC Noncompete Rule: Where Do We Go From Here?
On Tuesday, April 23, 2024, the Federal Trade Commission (FTC) voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Article
FTC Finalizes Rule Against Employee Noncompetes
On April 23, 2024, the Federal Trade Commission voted to finalize a rule abolishing the vast majority of employee noncompetes across the United States.
24 April 2024
Health Care Law Today
FDA Continues to Take Stance That it Will Not Issue CBD Rules
The FDA recently doubled down on its January 26, 2023 position that existing regulatory pathways for foods and dietary supplements are not appropriate to manage the risks of CBD and a new regulatory pathway is needed.